الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 177 |  |  |
| | | from | 177 | | |
Abstract
IBS is a functional gastrointestinal disorder characterized by abdominal pain, flatulence and changes in the bowel habits without clear organic dysfunctions and affects all age groups globally. The study was conducted to assess safety and effectiveness of ethosuximide and pentoxifylline in the treatment of abdominal pain related to irritable bowel syndrome. This study was a controlled,randomized and prospective study. Patients with IBS were recruited from Gastro-enterology Department at Tanta University Hospital, Egypt, from November 2019 to January 2021. Seventy five patients who fulfilled the inclusion criteria and had informed consent were randomized based on the days of hospital admission into three groups (n=25). group one serves as a control group that received mebverine hydrochloride 135 mg capsules t.i.d for three months (Coloverine, Chemi pharm ,Egypt). group two received mebverine 135 mg capsules t.i.d plus ethosuximide 500 mg capsules t.i.d for three months (Ethoxa 250 mg ,Delta pharm ,Egypt). group three received mebverine 135 mg t.i.d plus pentoxifylline 400 mg twice daily for three months (Trental 400mg , Sanovi Aventis, Egypt). Blood samples were collected before and after three months for determination of serum level IL-6, IL-8, TNF alpha, fecal MPO and fecal NGAL2 by enzyme linked immunosorbent assay. Also numeric pain rating score was calculated for each patient before and after three months of treatment. The obtained results showed that addition of ethosuximide or pentoxifylline to mebeverine significantly decrease serum level of IL-6 ( P < 0.0001), IL-8 ( P < 0.0001), TNF alpha ( P < 0.0001), fecal myeloperoxidase and fecal neutrophile gelatinase associated lipocaline 2 ( P < 0.0001). Results also revealed that ethosuximide and pentoxifylline significantly reduce numeric pain rating scale ( P < 0.001).